| | Important Notice Regarding the Availability of Proxy Materials for the Stockholders’ Meeting to Be Held Virtually, Via Live Webcast at www.virtualshareholdermeeting.com/ | | |
| | The proxy statement and the | | |
| | You are cordially invited to attend the virtual Annual Meeting. Whether or not you expect to attend the Annual Meeting, PLEASE VOTE YOUR SHARES. As an alternative to voting online at the Annual Meeting, you may vote via the internet, by telephone or, if you receive a paper proxy card, by mailing the completed proxy card. Voting instructions are provided in the Notice of Internet Availability of Proxy Materials, or, if you receive a paper proxy card by mail, the instructions are printed on your proxy card. | | |
| | Even if you have voted by proxy, you may still vote online if you attend the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote at the Annual Meeting, you must follow the instructions from such organization and will need to obtain a proxy issued in your name from that record holder. | | |
| | | Page | | ||||
Questions and Answers | | | | | 1 | | | |
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | 15 | | | ||
| | | | 15 | | | ||
| | | | 16 | | | ||
| | | | 17 | | | ||
| | | | 17 | | | ||
| | | | 18 | | | ||
| | | | 18 | | | ||
| | | | 18 | | | ||
| | | | 19 | | | ||
| | | | 19 | | | ||
| | | | | | |||
| | | | 22 | | | ||
| | | | | | |||
| | | | 23 | | | ||
| | | | 23 | | | ||
| | | | 24 | | | ||
| | | | 25 | | | ||
| | | | | | |||
| | | | | | |||
| | | | | | |||
| | | | | | |||
Securities Authorized For Issuance Under Equity Compensation Plans | | | | | 34 | | | |
| | | | | | |||
| | | | | | |||
| | | | | | |||
Independent Registered Public Accounting Firm’s Fees | | | | | 37 | | | |
| | | | 37 | | | ||
Security Ownership Of Certain Beneficial Owners and Management | | | | | 38 | | | |
| | | | | | |||
| | | | 40 | | | ||
| | | | 40 | | |
| | | Page | | ||||
| | | | 40 | | | ||
| | | | | | |||
| | | | 42 | | | ||
| | | | | | |||
| | | | | | |||
Householding Of Proxy Materials | | | | | 55 | | | |
Other Matters | | | | | 55 | | | |
| | | | | | |||
| | | | |||||
| | Internet proxy voting is provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies. | | |
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 3 | | | | | | 3 | | | | | | | | |
Part II: Demographics Background | | | | | | | | | | | | | | | | | | | |
African American or Black | | | | | | | | | | | | | | | | | | | |
Alaskan Native or Native American | | | | | | | | | | | | | | | | | | | |
Asian | | | | | | | | | | | | | | | | | | | |
Hispanic or Latino | | | | | | | | | | | | | | | | | | | |
Native Hawaiian or Pacific Islander | | | | | | | | | | | | | | | | | | | |
White | | | | | 2 | | | | | | 3 | | | | | | | | |
Two or More Races or Ethnicities | | | | | | | | | | | | | | | | | | | |
LGBTQ+ | | | | | | | | | | | | | | | | | | | |
Did Not Disclose Demographic Background | | | | | 1 | | | | | | | | | | | | | | |
Name | | | Audit | | | Compensation | | | Nominating and Corporate Governance | | |||||||||
Harrison M. Bains, Jr. | | | | | X* | | | | | | | | | ||||||
Jeffrey Ives, Ph.D. | | | | | | | | | | | X | | | | | | X | | |
Christopher Posner | | | | | X | | | | | | X | | | | | | | | |
Martin Vogelbaum | | | | | X | | | | | | X* | | | | | | X* | | |
Susan Shiff, Ph.D.† | | | | | | | | | | | X | | | | | | X | | |
Total meetings during 2020 | | | | | 4 | | | | | | 4 | | | | | | 2 | | |
Name | | | Audit | | | Compensation | | | Nominating and Corporate Governance | | |||||||||
Harrison M. Bains, Jr.(1) | | | | | X | | | | | | | | | ||||||
Jeffrey L. Ives, Ph.D. | | | | | X | | | | | | X | | | | | | X | | |
Martin Vogelbaum | | | | | X | | | | | | X* | | | | | | X* | | |
Susan Shiff, Ph.D. | | | | | | | | | | | X | | | | | | X | | |
Lisa von Moltke, M.D. | | | | | | | | | | | | | | | | | X | | |
Helen M. Boudreau(2) | | | | | X* | | | | | | | | | | | | | | |
Total meetings during 2023 | | | | | 4 | | | | | | 1 | | | | | | 1 | | |
Name | | | Age | | | Position(s) | |
| | | | President, Chief Executive Officer and Director | | ||
| | 54 | | | Chief | ||
| |||||||
Scott M. Terrillion | | | | | General Counsel, Secretary and Chief Compliance | ||
|
Name | | | Age | | | Position | |
Martin Vogelbaum | | | |||||
| | Director | | ||||
Jeffrey L. Ives, Ph.D. | | | |||||
| | Director | | ||||
Susan Shiff, Ph.D. | | | | | Director | | |
Lisa von Moltke, M.D. | | | 65 | | | Director | |
Helen M. Boudreau | | | 58 | | | Director | |
Director | | | Fees Earned or Paid in Cash(1) | | | Stock Awards(2)(4) | | | Option Awards(3)(4) | | | Total | | ||||||||||||
Martin Vogelbaum | | | | $ | 110,000 | | | | | $ | 224,928 | | | | | $ | 219,100 | | | | | $ | 554,028 | | |
Harrison M. Bains, Jr. | | | | | 60,000 | | | | | | 112,464 | | | | | | 109,550 | | | | | | 282,014 | | |
Jeffrey Ives, Ph.D. | | | | | 52,500 | | | | | | 112,464 | | | | | | 109,550 | | | | | | 274,514 | | |
Christopher Posner | | | | | 57,500 | | | | | | 112,464 | | | | | | 109,550 | | | | | | 279,514 | | |
Susan Shiff, Ph.D.(5) | | | | | 26,979 | | | | | | — | | | | | | 419,307 | | | | | | 446,286 | | |
Director | | | Fees Earned or Paid in Cash(3) ($) | | | Stock Awards(4)(5) ($) | | | Option Awards(4)(5) ($) | | | Total ($) | | ||||||||||||
Harrison M. Bains, Jr.(1) | | | | | 60,772 | | | | | | 99,999 | | | | | | 99,993 | | | | | | 260,764 | | |
Martin Vogelbaum | | | | | 120,000 | | | | | | 199,997 | | | | | | 199,989 | | | | | | 519,986 | | |
Jeffrey L. Ives, Ph.D. | | | | | 72,500 | | | | | | 99,999 | | | | | | 99,993 | | | | | | 272,492 | | |
Susan Shiff, Ph.D. | | | | | 62,500 | | | | | | 99,999 | | | | | | 99,993 | | | | | | 262,492 | | |
Lisa von Moltke, M.D. | | | | | 55,000 | | | | | | 99,999 | | | | | | 99,993 | | | | | | 254,992 | | |
Helen M. Boudreau(2) | | | | | 26,043 | | | | | | — | | | | | | 349,964 | | | | | | 376,007 | | |
Director | | | RSUs | | | Number of Shares Underlying Options | | ||||||
Martin Vogelbaum | | | | | 135,152 | | | | | | 257,616 | | |
Jeffrey L. Ives, Ph.D. | | | | | 64,638 | | | | | | 100,596 | | |
Susan Shiff, Ph.D. | | | | | 51,438 | | | | | | 110,757 | | |
Lisa von Moltke, M.D. | | | | | 32,362 | | | | | | 90,802 | | |
Helen M. Boudreau | | | | | — | | | | | | 155,747 | | |
| | | Member Annual Service Retainer | | | Chairperson / Lead Independent Director and Committee Chair Annual Service Retainer | | ||||||
Board of Directors | | | | $ | 40,000 | | | | | $ | 75,000 | | |
Audit Committee | | | | | 10,000 | | | | | | 20,000 | | |
Compensation Committee | | | | | 7,500 | | | | | | 15,000 | | |
Nominating and Corporate Governance Committee | | | | | 5,000 | | | | | | 10,000 | | |
| | | Member Annual Service Retainer | | | Chairperson / Lead Independent Director and Committee Chair Annual Service Retainer | | ||||||
Board of Directors | | | | $ | 50,000 | | | | | $ | 35,000 | | |
Audit Committee | | | | | 10,000 | | | | | | 20,000 | | |
Compensation Committee | | | | | 7,500 | | | | | | 15,000 | | |
Nominating and Corporate Governance Committee | | | | | 5,000 | | | | | | 10,000 | | |
| What we do: | | | What we do not do: | |
| ✓ Performance metrics tied to ✓ Multi-year vesting requirements. The equity awards we grant to our executive officers generally vest over multi-year periods, consistent with current market practice and our retention objectives. ✓ Double-trigger termination rights. Our agreements with our executive officers require both a change-in-control and a termination of employment for full severance benefits to be triggered. ✓ Independent compensation committee. Our compensation committee is comprised solely of independent members of our Board. ✓ Independent compensation consultant. Our compensation committee uses an independent compensation consultant that provides no other material services to the | | | ✘ No tax gross-ups. None of our ✘ No special perquisites. Except as otherwise discussed below, we generally do not provide our executives with perquisites or other personal benefits that differ materially from those available to employees generally. ✘ No retirement plans other than 401(k) ✘ No special health or welfare benefits. We do not provide our executives with any special health or welfare benefits. Our executive officers participate in the same broad-based company-sponsored health and welfare benefits programs ✘ Hedging, short selling and pledging prohibited. Our insider trading policy prohibits our executive officers and directors from hedging, short selling or pledging our securities. | |
and motivate a high-performing team of executive officers and by aligning most of the compensation of each of our executives with the Company’s short- and long-term performance, as well as each such executive’s individual contributions. We believe that it is important that performance- and equity-based compensation comprise a substantial portion of the total compensation of each of our executives in order to align our executives’ interests with those of our stockholders. The charts below illustrate the extent to which we weight compensation towards performance- and equity-based compensation. 2023 Say On Pay Vote At our 2023 annual meeting, we conducted a non-binding, advisory vote on executive compensation, commonly called a “say on pay” vote. We hold such a vote on an annual basis. Of the votes cast, approximately 78% were in favor of the say on pay proposal. We view this level of support as indicating generally positive feedback regarding our executive compensation program. Clawback Policy The Company adopted an incentive compensation clawback policy on November 28, 2023 that complies with the new SEC rules under the Dodd-Frank Wall Street Reform and Consumer Protection Act and related stock exchange listing rules. 2023 Summary Compensation Table The table below shows for the periods presented, compensation awarded to or paid to, or earned by, our named executive officers.
(1) Stock awards represent RSUs granted to the named executive officers. Each RSU represents the contingent right to receive one share of our common stock upon the satisfaction of the vesting conditions of the award, subject to the recipient’s continuous service through the vesting events. For 2022, the RSU grants consisted of a combination of time-based RSUs and performance-based RSUs, which vest upon the achievement of certain performance conditions. For 2023, the RSU grants consisted entirely of performance-based RSUs. In accordance with SEC rules, the amounts in the table above reflect the grant date fair values of the RSUs, calculated in accordance with ASC 718 for stock-based compensation transactions. In the case of performance-based awards, this grant date fair value is based on the probable outcome of the vesting conditions of these RSUs, determined as of the grant date. Assuming that all of the performance vesting conditions of the performance-based RSUs were met as of the grant date, the value of the performance-based RSUs granted during 2023 would have been $1,820,860, $402,400 and $402,400 for Mr. Posner, Mr. Maynard and Dr. Goncalves, respectively. See Note 15, Stock-Based Compensation in the notes to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 for a further description of our valuation methodology for equity awards. (2) Amounts reflect the grant date fair value of each option award granted, calculated in accordance with ASC 718. All of the option awards reported in the table above were granted under our 2014 Plan and | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Executive | | | 2020 Base Salary | | | Percentage Increase in Base Salary from 2019 | | ||||||
Derek Chalmers, Ph.D., D.Sc. | | | | $ | 576,800 | | | | | | 3% | | |
Frédérique Menzaghi, Ph.D. | | | | $ | 451,200 | | | | | | 3% | | |
Joana Goncalves, M.D. | | | | $ | 451,200 | | | | | | 3% | | |
Scott Terrillion | | | | $ | 412,000 | | | | | | 3% | | |
Richard Makara | | | | $ | 292,800 | | | | | | 3% | | |
| | | Target Bonus as Percentage of Base Salary (%) | | | Target Bonus ($) | | ||||||
Derek Chalmers, Ph.D., D.Sc. | | | | | 60 | | | | | | 346,080 | | |
Frédérique Menzaghi, Ph.D. | | | | | 40 | | | | | | 180,480 | | |
Joana Goncalves, M.D. | | | | | 40 | | | | | | 180,480 | | |
Scott Terrillion | | | | | 40 | | | | | | 164,800 | | |
Richard Makara | | | | | 40 | | | | | | 117,120 | | |
Thomas Reilly(1) | | | | | 40 | | | | | | 40,000 | | |
Named Executive Officer | | | Target Bonus % | | |||
Christopher Posner | | | | | 60 | | |
Ryan Maynard | | | | | 40 | | |
Joana Goncalves, M.D. | | | | | 40 | | |
Named Executive Officer | | | Annual Bonus Payment ($) | | | Percent of Target Bonus (%) | | ||||||
Derek Chalmers, Ph.D., D.Sc. | | | | | 432,600(1) | | | | | | 125 | | |
Frédérique Menzaghi, Ph.D. | | | | | 180,480 | | | | | | 100 | | |
Joana Goncalves, M.D. | | | | | 180,480 | | | | | | 100 | | |
Scott Terrillion | | | | | 164,800 | | | | | | 100 | | |
Richard Makara | | | | | 117,120(2) | | | | | | 100 | | |
Thomas Reilly | | | | | 40,000(3) | | | | | | 100 | | |
Executive | | | Stock Option Grant (# shares) | | |||
| | | | | | ||
| | | | | | ||
Joana Goncalves, M.D. | | | | | |||
| |
| | Performance-based RSUs (# shares) | | ||||||||||
| | Target | | | Stretch | | |||||||
Chris Posner | | | | | |||||||||
| | | | 56,000(2) | | | |||||||
Ryan Maynard | | | | | 27,000(1) | | | | | | 13,000(2) | | |
Joana Goncalves, M.D. | | | | | |||||||||
| | | | 13,000(2) | | |
| | | Performance-based RSUs (# shares) | | |||||||||
Executive | | | Target(1) | | | Stretch(2) | | ||||||
Derek Chalmers, Ph.D., D.Sc. | | | | | 50,000 | | | | | | 10,000 | | |
Frédérique Menzaghi, Ph.D. | | | | | 16,000 | | | | | | 10,000 | | |
Joana Goncalves, M.D. | | | | | 16,000 | | | | | | 10,000 | | |
Scott Terrillion | | | | | 16,000 | | | | | | 10,000 | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Number of Securities Underlying Unexercised Option (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(1) | | | Market Value of Shares of Units of Stock That Have Not Vested ($)(2) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)(3) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(2) | | |||||||||||||||||||||||||||
Christopher Posner President and Chief Executive Officer | | | | | 8/2/2018 | | | | | | 35,000 | | | | | | — | | | | | | 17.94 | | | | | | 08/02/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/4/2019 | | | | | | 9,000 | | | | | | — | | | | | | 20.47 | | | | | | 06/04/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 6/4/2020 | | | | | | 10,800 | | | | | | — | | | | | | 15.62 | | | | | | 06/04/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 6/3/2021 | | | | | | 10,800 | | | | | | — | | | | | | 13.06 | | | | | | 06/03/2031 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 10/29/2021 | | | | | | 283,000 | | | | | | 283,000(4) | | | | | | 16.83 | | | | | | 10/29/2031 | | | | | | 71,000(5) | | | | | | 52,753 | | | | | | — | | | | | | — | | | ||
| | | 2/25/2022 | | | | | | 55,458 | | | | | | 65,542(6) | | | | | | 10.46 | | | | | | 2/25/2032 | | | | | | 26,000(7) | | | | | | 19,318 | | | | | | — | | | | | | — | | | ||
| | | 3/1/2023 | | | | | | 46,875 | | | | | | 203,125(6) | | | | | | 10.06 | | | | | | 3/1/2033 | | | | | | — | | | | | | — | | | | | | 181,000 | | | | | | 134,483 | | | ||
Ryan Maynard Chief Financial Officer | | | | | 9/12/2022 | | | | | | 70,132 | | | | | | 154,688(8) | | | | | | 10.75 | | | | | | 9/12/2032 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 3/1/2023 | | | | | | 15,187 | | | | | | 65,813(6) | | | | | | 10.06 | | | | | | 3/1/2033 | | | | | | — | | | | | | — | | | | | | 40,000 | | | | | | 29,720 | | | ||
Joana Goncalves, M.D. former Chief Medical Officer | | | | | 10/22/2018 | | | | | | 250,000 | | | | | | — | | | | | | 19.27 | | | | | | 10/22/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/24/2020 | | | | | | 30,666 | | | | | | 1,334(6) | | | | | | 16.36 | | | | | | 02/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/30/2021 | | | | | | 22,000 | | | | | | 10,000(6) | | | | | | 20.59 | | | | | | 03/30/2031 | | | | | | 5,334(7) | | | | | | 3,963 | | | | | | — | | | | | | — | | | ||
| | | 2/25/2022 | | | | | | 36,666 | | | | | | 43,334(6) | | | | | | 10.46 | | | | | | 2/25/2032 | | | | | | 13,334(7) | | | | | | 9,907 | | | | | | — | | | | | | — | | | ||
| | | 3/1/2023 | | | | | | 15,187 | | | | | | 65,813(6) | | | | | | 10.06 | | | | | | 3/1/2033 | | | | | | — | | | | | | — | | | | | | 40,000 | | | | | | 29,720 | | |
Name and Principal Position | | | Year | | | Salary | | | Bonus | | | Stock Awards(1) | | | Option Awards(2) | | | Non-Equity Incentive Plan Compensation(3) | | | All Other Compensation(4) | | | Total | | ||||||||||||||||||||||||
Derek Chalmers, Ph.D., D.Sc. President and Chief Executive Officer | | | | | 2020 | | | | | $ | 576,800 | | | | | $ | 86,520(5) | | | | | $ | 818,000 | | | | | $ | 1,075,130 | | | | | $ | 346,080 | | | | | $ | 11,079 | | | | | $ | 2,913,609 | | |
| | | 2019 | | | | | | 560,000 | | | | | | — | | | | | | — | | | | | | 2,551,783 | | | | | | 310,800 | | | | | | 11,034 | | | | | | 3,433,617 | | | ||
| | | 2018 | | | | | | 542,100 | | | | | | — | | | | | | — | | | | | | 1,997,623 | | | | | | 238,524 | | | | | | 10,799 | | | | | | 2,789,046 | | | ||
Thomas Reilly(6) Chief Financial Officer | | | | | 2020 | | | | | | 100,000(7) | | | | | | 70,000(8) | | | | | | — | | | | | | 1,417,868 | | | | | | — | | | | | | 590 | | | | | | 1,588,458 | | |
Frédérique Menzaghi, Ph.D. Chief Scientific Officer and Senior Vice President, Research and Development | | | | | 2020 | | | | | | 451,200 | | | | | | — | | | | | | 261,760 | | | | | | 344,042 | | | | | | 323,349 | | | | | | 10,959 | | | | | | 1,391,310 | | |
| | | 2019 | | | | | | 438,000 | | | | | | — | | | | | | — | | | | | | 1,628,797 | | | | | | 148,920 | | | | | | 10,914 | | | | | | 2,226,631 | | | ||
| | | 2018 | | | | | | 400,000 | | | | | | — | | | | | | — | | | | | | 615,428 | | | | | | 212,000 | | | | | | 10,799 | | | | | | 1,238,227 | | |
Year | | | Summary Compensation Table Total for Christopher Posner(1) ($) | | | Summary Compensation Table Total for Derek Chalmers(1) ($) | | | Compensation Actually Paid to Christopher Posner(1)(2)(3) ($) | | | Compensation Actually Paid to Derek Chalmers(1)(2)(3) ($) | | | Average Summary Compensation Table Total for Non-PEO NEOs(1) ($) | | | Average Compensation Actually Paid to Non-PEO NEOs(1)(2)(3) ($) | | | Value of Initial Fixed $100 Investment based on TSR ($)(4) | | | Net Income ($ Millions) | | ||||||||||||||||||||||||
2023 | | | | | 4,743,329 | | | | | | — | | | | | | (2,735,603) | | | | | | — | | | | | | 1,661,327 | | | | | | (817,170) | | | | | | 4.91 | | | | | | (11.85) | | |
2022 | | | | | 2,509,979 | | | | | | — | | | | | | 1,365,402 | | | | | | — | | | | | | 1,719,829 | | | | | | 1,953,544 | | | | | | 70.98 | | | | | | (85.5) | | |
2021 | | | | | 9,901,376 | | | | | | 10,196,785 | | | | | | 6,770,961 | | | | | | 3,949,591 | | | | | | 1,467,504 | | | | | | 1,099,179 | | | | | | 80.50 | | | | | | (88.4) | | |
Name and Principal Position | | | Year | | | Salary | | | Bonus | | | Stock Awards(1) | | | Option Awards(2) | | | Non-Equity Incentive Plan Compensation(3) | | | All Other Compensation(4) | | | Total | | ||||||||||||||||||||||||
Joana Goncalves, M.D.(6) Chief Medical Officer | | | | | 2020 | | | | | | 451,200 | | | | | | — | | | | | | 261,760 | | | | | | 344,042 | | | | | | 270,789 | | | | | | 10,911 | | | | | | 1,338,702 | | |
Scott Terrillion(6) General Counsel, Secretary and Chief Compliance Officer | | | | | 2020 | | | | | | 412,000 | | | | | | — | | | | | | 261,760 | | | | | | 344,042 | | | | | | 164,800 | | | | | | 11,079 | | | | | | 1,193,681 | | |
| | | 2019 | | | | | | 400,000 | | | | | | — | | | | | | — | | | | | | 814,399 | | | | | | 160,000 | | | | | | 11,034 | | | | | | 1,385,433 | | | ||
Richard Makara(6) VP, Head of Accounting and Controller | | | | | 2020 | | | | | | 292,800 | | | | | | 117,120 | | | | | | — | | | | | | 322,539 | | | | | | — | | | | | | 10,509 | | | | | | 742,968 | | |
| | 2021 | | | | 2022 – 2023 | | |
| | Frédérique Menzaghi, Ph.D. | | | | Joana Goncalves, M.D. | | |
| | Joana Goncalves, M.D. | | | | Ryan Maynard | | |
| | Scott Terrillion | | | | | | |
| | Thomas Reilly | | | | | | |
Year | | | Summary Compensation Table Total for PEO 1 ($) | | | Exclusion of Stock Awards and Option Awards for PEO 1 ($) | | | Inclusion of Equity Values for PEO 1 ($) | | | Compensation Actually Paid to PEO 1 ($) | | ||||||||||||
2023 | | | | | 4,743,329 | | | | | | (3,589,860) | | | | | | (3,889,072) | | | | | | (2,735,603) | | |
Year | | | Average Summary Compensation Table Total for Non-PEO NEOs ($) | | | Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs ($) | | | Average Inclusion of Equity Values for Non-PEO NEOs ($) | | | Average Compensation Actually Paid to Non-PEO NEOs ($) | | ||||||||||||
2023 | | | | | 1,661,327 | | | | | | (975,556) | | | | | | (1,502,941) | | | | | | (817,170) | | |
Year | | | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for PEO 1 ($) | | | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for PEO 1 ($) | | | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for PEO 1 ($) | | | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for PEO 1 ($) | | | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for PEO 1 ($) | | | Total – Inclusion of Equity Values for PEO 1 ($) | | ||||||||||||||||||
2023 | | | | | 157,175 | | | | | | (3,218,622) | | | | | | 74,225 | | | | | | (901,850) | | | | | | — | | | | | | (3,889,072) | | |
Year | | | Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($) | | | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs ($) | | | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($) | | | Total – Average Inclusion of Equity Values for Non-PEO NEOs ($) | | ||||||||||||||||||
2023 | | | | | 40,895 | | | | | | (1,076,410) | | | | | | 24,047 | | | | | | (491,473) | | | | | | — | | | | | | (1,502,941) | | |
| | | | | | | | | Estimated Future Payouts under Non-Equity Incentive Plan Awards(1) | | | Estimated Future Payouts under Equity Incentive Plan Awards(2) | | | All Other Stock Awards: Number of Shares of Stock or Units (#)(3) | | | All Other Option Awards: Number of Securities Underlying Options (#) | | | Exercise or Base Price of Option Awards ($/Share) | | | Grant Date Fair Value of Stock and Option Awards ($)(4) | | ||||||||||||||||||||||||||||||||||||
Name | | | Grant Date | | | Threshold ($) | | | Target ($) | | | Threshold (#) | | | Target (#) | | | Maximum (#) | | ||||||||||||||||||||||||||||||||||||||||||
Derek Chalmers, Ph.D., D.Sc. | | | | | | | | | | | N/A | | | | | | 346,080 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | 12,500 | | | | | | 50,000 | | | | | | 60,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 50,000 | | | | | | | | | | | | | | | | | | 818,000 | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 100,000 | | | | | | 16.36 | | | | | | 1,075,130 | | | ||
Thomas Reilly | | | | | 10/1/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 175,000 | | | | | | 12.74 | | | | | | 1,417,868 | | |
Frédérique Menzaghi, Ph.D. | | | | | | | | | | | N/A | | | | | | 180,480 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | 90,309 | | | | | | 180,618 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | 8,000 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,000 | | | | | | | | | | | | | | | | | | 261,760 | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,000 | | | | | | 16.36 | | | | | | 344,042 | | | ||
Joana Goncalves, M.D. | | | | | | | | | | | N/A | | | | | | 180,480 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | 90,309 | | | | | | 180,618 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | 4,000 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,000 | | | | | | | | | | | | | | | | | | 261,760 | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,000 | | | | | | 16.36 | | | | | | 344,042 | | | ||
Scott Terrillion | | | | | | | | | | | N/A | | | | | | 164,800 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | 4,000 | | | | | | 16,000 | | | | | | 26,000 | | | | | | | | | | | | | | | | | | | | | | | | 0 | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,000 | | | | | | | | | | | | | | | | | | 261,760 | | | ||
| | | 2/24/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 32,000 | | | | | | 16.36 | | | | | | 344,042 | | | ||
Richard Makara | | | | | 2/24/2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 30,000 | | | | | | 16.36 | | | | | | 322,539 | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant date | | | Number of Securities Underlying Unexercised Options Exercisable | | | Number of Securities Underlying Unexercised Options Unexercisable | | | Option Exercise Price | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested(3) | | | Market Value of Shares of Units of Stock That Have Not Vested(4) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (5) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(4) | | |||||||||||||||||||||||||||
Derek Chalmers, Ph.D., D.Sc. President and Chief Executive Officer | | | | | 1/30/2014 | | | | | | 80,000 | | | | | | — | | | | | $ | 11.00 | | | | | | 1/30/2024 | | | | | | — | | | | | $ | — | | | | | | — | | | | | | — | | |
| | | 6/15/2015 | | | | | | 165,000 | | | | | | — | | | | | | 10.82 | | | | | | 6/15/2025 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/30/2016 | | | | | | 191,000 | | | | | | — | | | | | | 6.00 | | | | | | 3/30/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/8/2017 | | | | | | 210,937 | | | | | | 14,063(1) | | | | | | 17.41 | | | | | | 3/8/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/9/2018 | | | | | | 128,906 | | | | | | 58,594(1) | | | | | | 14.39 | | | | | | 3/9/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 102,812 | | | | | | 132,188(1) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 20,833 | | | | | | 79,167(1) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 50,000 | | | | | | 756,500 | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 41,250 | | | | | | 624,113 | | | ||
Thomas Reilly Chief Financial Officer | | | | | 10/1/2020 | | | | | | — | | | | | | 175,000(2) | | | | | | 12.74 | | | | | | 10/1/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||
Frédérique Menzaghi, Ph.D. Chief Scientific Officer and Senior Vice President, Research and Development | | | | | 1/30/2014 | | | | | | 40,000 | | | | | | — | | | | | | 11.00 | | | | | | 1/30/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 6/15/2015 | | | | | | 60,000 | | | | | | — | | | | | | 10.82 | | | | | | 6/15/2025 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/30/2016 | | | | | | 65,000 | | | | | | — | | | | | | 6.00 | | | | | | 3/30/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/8/2017 | | | | | | 70,312 | | | | | | 4,688(1) | | | | | | 17.41 | | | | | | 3/8/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/9/2018 | | | | | | 39,703 | | | | | | 18,047(1) | | | | | | 14.39 | | | | | | 3/9/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 65,625 | | | | | | 84,375(1) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 6,666 | | | | | | 25,334(1) | | | | | | 16.36 | | | | | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 16,000 | | | | | | 242,080 | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 18,000 | | | | | | 272,340 | | | ||
Joana Goncalves, M.D. Chief Medical Officer | | | | | 10/22/2018 | | | | | | 135,416 | | | | | | 114,584(2) | | | | | | 19.27 | | | | | | 10/22/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 2/24/2020 | | | | | | 6,666 | | | | | | 25,334(1) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 16,000 | | | | | | 242,080 | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 22,000 | | | | | | 332,860 | | | ||
Scott M. Terrillion General Counsel, Secretary and Chief Compliance Officer | | | | | 11/28/2016 | | | | | | 135,000 | | | | | | — | | | | | | 9.22 | | | | | | 11/28/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 3/9/2018 | | | | | | 31,968 | | | | | | 14,532(1) | | | | | | 14.39 | | | | | | 3/9/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 32,812 | | | | | | 42,188(1) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | ��� | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 6,666 | | | | | | 25,334(1) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 16,000 | | | | | | 242,080 | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 20,000 | | | | | | 302,600 | | |
| | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Grant date | | | Number of Securities Underlying Unexercised Options Exercisable | | | Number of Securities Underlying Unexercised Options Unexercisable | | | Option Exercise Price | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested(3) | | | Market Value of Shares of Units of Stock That Have Not Vested(4) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (5) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(4) | | |||||||||||||||||||||||||||
Richard Makara Vice President, Head of Accounting & Controller | | | | | 10/17/2014 | | | | | | 25,000 | | | | | | — | | | | | | 8.03 | | | | | | 10/17/2024 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | 3/30/2016 | | | | | | 9,167 | | | | | | — | | | | | | 6.00 | | | | | | 3/30/2026 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/8/2017 | | | | | | 18,750 | | | | | | 1,250(1) | | | | | | 17.41 | | | | | | 3/8/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 8/17/2017 | | | | | | 16,666 | | | | | | 3,334(1) | | | | | | 13.51 | | | | | | 8/17/2027 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2018 | | | | | | 13,750 | | | | | | 6,250(1) | | | | | | 14.18 | | | | | | 3/6/2028 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3/6/2019 | | | | | | 13,125 | | | | | | 16,875(1) | | | | | | 16.10 | | | | | | 3/6/2029 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 2/24/2020 | | | | | | 6,250 | | | | | | 23,750(1) | | | | | | 16.36 | | | | | | 2/24/2030 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | Stock Awards | | |||||||||
Name | | | Number of Shares Acquired on Vesting (#) | | | Value Realized on Vesting ($) | | ||||||
Derek Chalmers, Ph.D., D.Sc. | | | | | 38,750 | | | | | | 587,575 | | |
Thomas Reilly | | | | | — | | | | | | — | | |
Frédérique Menzaghi, Ph.D. | | | | | 45,500 | | | | | | 675,350 | | |
Joana Goncalves, M.D. | | | | | 34,000 | | | | | | 556,300 | | |
Scott M. Terrillion | | | | | 14,334 | | | | | | 216,376 | | |
Richard Makara | | | | | — | | | | | | — | | |
Name | | | Benefit(1) | | | Termination without Cause(1) | | | Resignation for Good Reason(1) | | | CIC Termination(1) | | |||||||||
Derek Chalmers, Ph.D., D.Sc. | | | Severance Payments | | | | $ | 576,800 | | | | | $ | 576,800 | | | | | $ | 576,800 | | |
| Payment of Employer Health Insurance Continuation | | | | | 729 | | | | | | 729 | | | | | | 729 | | | ||
| Target Bonus | | | | | 346,080 | | | | | | 346,080 | | | | | | 346,080 | | | ||
| Vesting Acceleration | | | | | — | | | | | | — | | | | | | 1,423,972 | | | ||
| Benefit Total | | | | $ | 923,609 | | | | | $ | 923,609 | | | | | $ | 2,347,581 | | | ||
Frédérique Menzaghi, Ph.D. | | | Severance Payments | | | | $ | 225,600 | | | | | | — | | | | | $ | 225,600 | | |
| Payment of Employer Health Insurance Continuation | | | | | 609 | | | | | | — | | | | | | 609 | | | ||
| Target Bonus | | | | | 180,480 | | | | | | — | | | | | | 180,480 | | | ||
| Vesting Acceleration | | | | | — | | | | | | — | | | | | | 527,775 | | | ||
| Benefit Total | | | | $ | 406,689 | | | | | | — | | | | | $ | 934,464 | | | ||
Joana Goncalves, M.D.(2) | | | Severance Payments | | | | $ | 338,400 | | | | | | — | | | | | $ | 338,400 | | |
| Payment of Employer Health Insurance Continuation | | | | | 561 | | | | | | — | | | | | | 561 | | | ||
| Target Bonus | | | | | 180,480 | | | | | | — | | | | | | 180,480 | | | ||
| Vesting Acceleration | | | | | — | | | | | | — | | | | | | 574,940 | | | ||
| Benefit Total | | | | $ | 519,441 | | | | | | — | | | | | $ | 1,094,381 | | | ||
Thomas Reilly(3) | | | Severance Payments(3) | | | | $ | 100,000 | | | | | | — | | | | | $ | 100,000 | | |
| Payment of Employer Health Insurance Continuation(3) | | | | | 140 | | | | | | — | | | | | | 140 | | | ||
| Target Bonus(3) | | | | | 40,000 | | | | | | — | | | | | | 40,000 | | | ||
| Vesting Acceleration | | | | | — | | | | | | — | | | | | | 418,250 | | | ||
| Benefit Total | | | | $ | 140,140 | | | | | | — | | | | | $ | 558,390 | | |
Plan Category | | Number of securities to be issued upon exercise of outstanding options (a) | | Weighted-average exercise price of outstanding options, warrants and rights (b)(2) | | Number of securities remaining available for future issuance under equity compensation plans (excluding shares of common stock reflected in column (a))(c) | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) | | Weighted- average exercise price of outstanding options, warrants and rights (b)(2) | | Number of securities remaining available for future issuance under equity compensation plans (excluding shares of common stock reflected in column (a))(c)(4) | | ||||||||||||||||||||||||
Equity compensation plans approved by security holders (1) | | | | 5,421,893 | | | | $ | 14.93 | | | | | 284,380(3) | | | | | | 8,463,971(3) | | | | | 12.12 | | | | | 1,252,843 | | | ||||||
Equity compensation plans not approved by security holders (4) | | | | 47,500 | | | | $ | 25.88 | | | | | 252,500 | | | ||||||||||||||||||||||
Equity compensation plans not approved by security holders | | | | — | | | | | — | | | | | 300,000(5) | | | ||||||||||||||||||||||
Total | | | | 5,469,393 | | | | $ | 15.02 | | | | | 536,880 | | | | | | 8,463,971 | | | | | 12.12 | | | | | 1,552,843 | | |
| | Year Ended December 31, | | | Year ended December 31, | | ||||||||||||||||||||
| | 2020 | | 2019 | | | 2023 | | 2022 | | ||||||||||||||||
| | (in thousands) | | | (in thousands) | | ||||||||||||||||||||
Audit fees(a) | | | $ | 616 | | | | $ | 776 | | | |||||||||||||||
Audit-related fees | | | | — | | | | | — | | | |||||||||||||||
Tax fees | | | | — | | | | | — | | | |||||||||||||||
All other fees | | | | — | | | | | — | | | |||||||||||||||
Audit Fees(1) | | | $ | 1,039 | | | | $ | 870 | | | |||||||||||||||
Total | | | $ | 616 | | | | $ | 776 | | | | | $ | 1,039 | | | | $ | 870 | | |
Name of beneficial owner | | | Number of Shares Beneficially Owned | | | Percentage of Shares Beneficially Owned | | ||||||
5% stockholders: | | | | | | | | | | | | | |
T. Rowe Price(1) | | | | | 2,429,235 | | | | | | 4.9% | | |
Blackrock, Inc.(2) | | | | | 3,632,266 | | | | | | 7.3 | | |
Rho Ventures VI, LP(3) | | | | | 2,799,058 | | | | | | 5.6 | | |
First Manhattan Co.(4) | | | | | 3,212,796 | | | | | | 6.4 | | |
Vifor (International) Ltd.(5) | | | | | 4,114,379 | | | | | | 8.2 | | |
Directors and named executive officers: | | | | | | | | | | | | | |
Derek Chalmers, Ph.D., D.Sc.(6) | | | | | 1,889,448 | | | | | | 3.7 | | |
Thomas Reilly | | | | | — | | | | | | — | | |
Frédérique Menzaghi, Ph.D.(7) | | | | | 486,954 | | | | | | 1.0 | | |
Scott M. Terrillion(8) | | | | | 264,446 | | | | | | * | | |
Joana Goncalves(9) | | | | | 192,735 | | | | | | * | | |
Richard Makara(10) | | | | | 117,250 | | | | | | * | �� | |
Martin Vogelbaum(11) | | | | | 126,500 | | | | | | * | | |
Harrison M. Bains, Jr.(12) | | | | | 114,500 | | | | | | * | | |
Jeffrey Ives, Ph.D.(13) | | | | | 83,500 | | | | | | * | | |
Christopher Posner(14) | | | | | 54,310 | | | | | | * | | |
Susan Shiff, Ph.D.(15) | | | | | 9,500 | | | | | | * | | |
All current executive officers and directors as a group (10 persons)(16) | | | | | 3,221,893 | | | | | | 6.2% | | |
Name of beneficial owner | | | Number of Shares Beneficially Owned | | | Percentage of Shares Beneficially Owned | | ||||||
5% stockholders: | | | | | | | | | | | | | |
Vifor (International) Ltd(1) | | | | | 7,396,770 | | | | | | 13.5% | | |
Blackrock, Inc.(2) | | | | | 3,554,258 | | | | | | 6.5% | | |
Directors and named executive officers: | | | | | | | | | | | | | |
Christopher Posner(3) | | | | | 674,599 | | | | | | 1.2% | | |
Ryan Maynard(4) | | | | | 125,387 | | | | | | * | | |
Joana Goncalves, M.D.(5) | | | | | 419,055 | | | | | | * | | |
Martin Vogelbaum(6) | | | | | 192,681 | | | | | | * | | |
Helen M. Boudreau(7) | | | | | 38,936 | | | | | | * | | |
Jeffrey L. Ives, Ph.D.(8) | | | | | 116,072 | | | | | | * | | |
Susan Shiff, Ph.D.(9) | | | | | 81,272 | | | | | | * | | |
Lisa von Moltke, M.D.(10) | | | | | 65,796 | | | | | | * | | |
All current executive officers and directors as a group (8 persons)(11) | | | | | 1,739,035 | | | | | | 3.1% | | |
Status | | | Number of Shares of Common Stock Authorized | | | Number of Shares of Common Stock Issued and Outstanding | | | Number of Shares of Common Stock Reserved for Future Issuance | | | Number of Shares of Common Stock Authorized but Unissued and Unreserved | | ||||||||||||
Pre-Reverse Stock Split | | | | | 200,000,000 | | | | | | 54,667,079 | | | | | | 11,464,860 | | | | | | 133,868,061 | | |
Post-Reverse Stock Split 1:4 | | | | | 50,000,000 | | | | | | 13,666,769 | | | | | | 2,866,215 | | | | | | 33,467,016 | | |
Post-Reverse Stock Split 1:5 | | | | | 40,000,000 | | | | | | 10,933,415 | | | | | | 2,292,972 | | | | | | 26,773,613 | | |
Post-Reverse Stock Split 1:6 | | | | | 33,333,333 | | | | | | 9,111,179 | | | | | | 1,910,810 | | | | | | 22,311,344 | | |
Post-Reverse Stock Split 1:7 | | | | | 28,571,429 | | | | | | 7,809,582 | | | | | | 1,637,837 | | | | | | 19,124,010 | | |
Post-Reverse Stock Split 1:8 | | | | | 25,000,000 | | | | | | 6,833,384 | | | | | | 1,433,107 | | | | | | 16,733,509 | | |
Post-Reverse Stock Split 1:9 | | | | | 22,222,222 | | | | | | 6,074,119 | | | | | | 1,273,873 | | | | | | 14,874,230 | | |
Post-Reverse Stock Split 1:10 | | | | | 20,000,000 | | | | | | 5,466,707 | | | | | | 1,146,486 | | | | | | 13,386,807 | | |
Post-Reverse Stock Split 1:11 | | | | | 18,181,818 | | | | | | 4,969,734 | | | | | | 1,042,260 | | | | | | 12,169,824 | | |
Post-Reverse Stock Split 1:12 | | | | | 16,666,667 | | | | | | 4,555,589 | | | | | | 955,405 | | | | | | 11,155,673 | | |
Status | | | Number of Shares of Common Stock Authorized | | | Number of Shares of Common Stock Issued and Outstanding | | | Number of Shares of Common Stock Reserved for Future Issuance | | | Number of Shares of Common Stock Authorized but Unissued and Unreserved | | ||||||||||||
Pre-Reverse Stock Split | | | | | 100,000,000 | | | | | | 54,667,079 | | | | | | 11,464,860 | | | | | | 33,868,061 | | |
Post-Reverse Stock Split 1:4 | | | | | 25,000,000 | | | | | | 13,666,769 | | | | | | 2,866,215 | | | | | | 8,467,016 | | |
Post-Reverse Stock Split 1:5 | | | | | 20,000,000 | | | | | | 10,933,415 | | | | | | 2,292,972 | | | | | | 6,773,613 | | |
Post-Reverse Stock Split 1:6 | | | | | 16,666,667 | | | | | | 9,111,179 | | | | | | 1,910,810 | | | | | | 5,644,678 | | |
Post-Reverse Stock Split 1:7 | | | | | 14,285,714 | | | | | | 7,809,582 | | | | | | 1,637,837 | | | | | | 4,838,295 | | |
Post-Reverse Stock Split 1:8 | | | | | 12,500,000 | | | | | | 6,833,384 | | | | | | 1,433,107 | | | | | | 4,233,509 | | |
Post-Reverse Stock Split 1:9 | | | | | 11,111,111 | | | | | | 6,074,119 | | | | | | 1,273,873 | | | | | | 3,763,119 | | |
Post-Reverse Stock Split 1:10 | | | | | 10,000,000 | | | | | | 5,466,707 | | | | | | 1,146,486 | | | | | | 3,386,807 | | |
Post-Reverse Stock Split 1:11 | | | | | 9,090,909 | | | | | | 4,969,734 | | | | | | 1,042,260 | | | | | | 3,078,915 | | |
Post-Reverse Stock Split 1:12 | | | | | 8,333,333 | | | | | | 4,555,589 | | | | | | 955,405 | | | | | | 2,822,339 | | |
By: | |
By: | |